We report on 2 patients with ophthalmologic complications associated with mild iron deficiency anemia. Case 1, a 37-year-old female patient, presented after 4 days of blurred vision in her left eye. Ophthalmoscopic and angiographic findings were consistent with the diagnosis of central retinal vein occlusion (CRVO). Further hematologic investigation into possible causes disclosed mild iron deficiency anemia (Hb 9.4 g/dl, hematocrit 30.5%). After the patient’s visual acuity had worsened progressively to 20/50, an initial thrombolytic treatment and continuous intravenous heparinization was started on day 8, followed by oral substitution therapy with ferrous sulfate. On day 14, her visual acuity recovered to 20/20 OS and remained stable during follow-up. Case 2, a 50-year-old female patient, presented with a 1-week-history of blurred vision and metamorphopsia. Her visual acuity was 20/200. Further examination revealed a nonarteritic ischemic optic neuropathy and an iron deficiency anemia as the underlying disease (Hb 7.3 g/dl, hematocrit 25%). Despite intravenous heparinization and systemic treatment with steroids, there was no improvement in visual acuity. Clinicians involved in the management of chronic iron deficiency anemia should be aware of possible ophthalmic manifestations in this disease.

1.
Kirkham TH, Wrigley PFM, Holt JM: Central retinal vein occlusion complicating iron deficiency anemia. Br J Ophthalmol 1971;55:777–780.
2.
Matsuoka Y, Hayasaka S, Yamada K: Incomplete occlusion of central retinal artery in a girl with iron deficiency anemia. Ophthalmologica 1996;210:358–360.
3.
Hattenbach LO, Steinkamp GWK, Scharrer I, Ohrloff Ch: Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 1998;212:394–398.
4.
Bill A: Some aspects of the ocular circulation. Friedenwald lecture. Invest Ophthalmol Vis Sci 1985;26:410–424.
5.
Chabanel A, Glacet-Bernard A, Lelong F, Taccoen A, Coscas G, Samama MM: Increased red blood cell aggregation in retinal vein occlusion. Br J Ophthalmol 1990;75:127–131.
6.
Szarfarc SC, de Souza SB: Prevalence and risk factors in iron deficiency and anemia. Arch Latinoam Nutr 1997;47:35–38.
7.
Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL: Prevalence of iron deficiency in the United States. JAMA 1997;277:973–976.
8.
Quintas ME, Requejo AM, Ortega RM, Redondo MR, Lopez-Sobaler AM, Gaspar MJ: The female Spanish population: A group at risk of nutritional iron deficiency. Int J Food Sci Nutr 1997;48:271–279.
9.
Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998;47:1–29.
10.
Milman N, Clausen J, Byg KE: Iron status in 268 Danish women aged 18–30 years: Influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77:13–19.
11.
Klewin KM, Appen RE, Kaufman PL: Amaurosis and blood loss. Am J Ophthalmol 1978;86:669–672.
12.
Shibuya Y, Hayasaka S: Central retinal vein occlusion in a patient with anorexia nervosa. Am J Ophthalmol 1995;119:109–110.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.